
0:00
48:53
Several phase 3 trials in high-risk localized prostate cancer have reported this year including PROTEUS and DASL. The panel debates if and how these will impact treatment of this patient population.
More episodes from "The Uromigos"



Don't miss an episode of “The Uromigos” and subscribe to it in the GetPodcast app.








